On BBC Radio 5 Live, Owkin co-founder and CEO Thomas Clozel explains our new AI project to better detect HER2-positive breast cancer
Today our co-founder and CEO Thomas Clozel joined Naga Munchetty on B Radio to discuss our new project to develop hashtag#AI models to better detect HER2-positive breast cancer in women.
About Owkin
Owkin is building the first universal AI co-pilot called K to lay the foundation for Biological Artificial Superintelligence (BASI). This co-pilot integrates a suite of AI agents that decode complex biology, accelerate research, and dramatically increase productivity. Acting as copilots, Owkin K agents will automate drug discovery and diagnostics and power next-generation pharma companies.
Owkin K will be powered by the world’s largest federated multimodal patient data network, a robotized lab, leading AGI technologies, and cutting-edge multimodal foundation models and LLMs.
